{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:16:15Z","timestamp":1783617375885,"version":"3.55.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Science and Technology Projects of China","award":["2025ZD0551703"],"award-info":[{"award-number":["2025ZD0551703"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Colorectal cancer (CRC) poses a significant challenge to public health worldwide. Mounting evidence implicates fatty liver disease as an accelerator of CRC. This study investigated the association between the Framingham Steatosis Index (FSI), also known as the Fatty Liver Substitution Index, and CRC susceptibility. This study aims to provide a theoretical foundation for developing preventive strategies and therapeutic interventions for individuals at high risk of CRC, thereby ultimately improving treatment outcomes. This study employed 1,01,316 baseline records from the NHANES database (1999\u20132018). The application of stringent eligibility criteria yielded 42,732 qualified subjects: 274 individuals with CRC and 42,458 control individuals. FSI quantification was performed using standardized procedures. Following covariate adjustment, analyses were performed using multivariate logistic regression, restricted cubic spline models, and stratification approaches to ascertain the relationship between FSI scores and CRC susceptibility. Within crude models, increased FSI levels were positively associated with CRC susceptibility, maintaining this direct association after covariate adjustment. Subgroup evaluations generated uniformly consistent findings across population categories, confirming the robustness of the findings. Dose-response analyses revealed a significant linear correlation, in which an increase in FSI magnitude corresponded to a heightened CRC probability. Increasing FSI levels increase the risk of developing CRC, providing new theoretical support for the diagnosis and treatment of CRC. However, cross-sectional studies aim to establish associations, and the causal relationship between the 2 requires further research to validate and assess the feasibility of applying these findings in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049536","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:00:45Z","timestamp":1783098045000},"page":"e49536","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Linear relationship between the Framingham Steatosis Index (FSI) and colorectal cancer (1999\u20132018): A nationwide cross-sectional study based on NHANES"],"prefix":"10.1097","volume":"105","author":[{"given":"Binxu","family":"Wang","sequence":"first","affiliation":[{"name":"Clinical Specialty in Integrative Chinese and Western Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingchao","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Specialty in Integrative Chinese and Western Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"He","sequence":"additional","affiliation":[{"name":"Clinical Specialty in Integrative Chinese and Western Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Xing","sequence":"additional","affiliation":[{"name":"Clinical Specialty in Integrative Chinese and Western Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-3954","authenticated-orcid":false,"given":"Bowen","family":"Sui","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260709","first-page":"17","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20260709","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.3390\/cancers15164154","article-title":"Inflammatory bowel disease and colorectal cancer: epidemiology, etiology, surveillance, and management.","volume":"15","author":"Sato","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R3-20260709","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.giec.2021.12.008","article-title":"Risk factors for colorectal polyps and cancer.","volume":"32","author":"Sninsky","year":"2022","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"R4-20260709","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0032-1306421","article-title":"Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research.","volume":"32","author":"Kleiner","year":"2012","journal-title":"Semin Liver Dis"},{"key":"R5-20260709","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R6-20260709","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s12072-024-10660-y","article-title":"MAFLD as part of systemic metabolic dysregulation.","volume":"18","author":"Zhao","year":"2024","journal-title":"Hepatol Int"},{"key":"R7-20260709","doi-asserted-by":"crossref","first-page":"671","DOI":"10.21037\/hbsn-21-546","article-title":"Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.","volume":"12","author":"Yuan","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R8-20260709","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/postgradmedj-2016-134383","article-title":"Non-alcoholic fatty liver disease and colorectal cancer.","volume":"93","author":"Mikolasevic","year":"2017","journal-title":"Postgrad Med J"},{"key":"R9-20260709","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.metabol.2015.11.008","article-title":"Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.","volume":"65","author":"Brown","year":"2016","journal-title":"Metabolism"},{"key":"R10-20260709","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-981-10-8684-7_9","article-title":"Microbiota, obesity and NAFLD.","volume":"1061","author":"Lau","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"R11-20260709","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5217\/ir.2018.16.3.338","article-title":"Intestinal microbiota, chronic inflammation, and colorectal cancer.","volume":"16","author":"Park","year":"2018","journal-title":"Intest Res"},{"key":"R12-20260709","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).","volume":"17","year":"2024","journal-title":"Obes Facts"},{"key":"R13-20260709","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/jcm10030520","article-title":"External validation of surrogate indices of fatty liver in the general population: the Bagnacavallo study.","volume":"10","author":"Foschi","year":"2021","journal-title":"J Clin Med"},{"key":"R14-20260709","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/diagnostics11010132","article-title":"Prediction of nonalcoholic fatty liver disease using noninvasive and non-imaging procedures in Japanese health checkup examinees.","volume":"11","author":"Murayama","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R15-20260709","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.cgh.2016.03.034","article-title":"Development and validation of the Framingham steatosis index to identify persons with hepatic steatosis.","volume":"14","author":"Long","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R16-20260709","doi-asserted-by":"crossref","first-page":"101567","DOI":"10.1016\/j.clinre.2020.10.011","article-title":"The Ability of the Framingham Steatosis Index (FSI) to predict non-alcoholic fatty liver disease (NAFLD): a cohort study.","volume":"45","author":"Motamed","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R17-20260709","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.3390\/jcm9092851","article-title":"Comparative assessment and external validation of hepatic steatosis formulae in a community-based setting.","volume":"9","author":"Jung","year":"2020","journal-title":"J Clin Med"},{"key":"R18-20260709","first-page":"1","article-title":"National health and nutrition examination survey: analytic guidelines, 1999-2010.","author":"Johnson","year":"2013","journal-title":"Vital Health Stat 2"},{"key":"R19-20260709","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3945\/an.115.009258","article-title":"Update on NHANES dietary data: focus on collection, release, analytical considerations, and uses to inform public policy.","volume":"7","author":"Ahluwalia","year":"2016","journal-title":"Adv Nutr"},{"key":"R20-20260709","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s12883-022-02989-4","article-title":"Evaluation of De Ritis (AST\/ALT), ALP\/ALT, and AST\/ALP ratios as prognostic factors in patients with acute ischemic stroke.","volume":"22","author":"Ahmadabad","year":"2022","journal-title":"BMC Neurol"},{"key":"R21-20260709","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.envint.2011.05.016","article-title":"Impact of cigarette smoking on volatile organic compound (VOC) blood levels in the U.S. population: NHANES 2003-2004.","volume":"37","author":"Chambers","year":"2011","journal-title":"Environ Int"},{"key":"R22-20260709","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cld.2017.08.003","article-title":"The natural history of nonalcoholic fatty liver disease-an evolving view.","volume":"22","author":"Lindenmeyer","year":"2018","journal-title":"Clin Liver Dis"},{"key":"R23-20260709","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2018.06.004","article-title":"Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis.","volume":"87","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"key":"R24-20260709","doi-asserted-by":"crossref","first-page":"e23027","DOI":"10.1590\/s0004-2803.24612023-027","article-title":"Non-alcoholic fatty liver disease and extra-hepatic cancer: a narrative review.","volume":"61","author":"Rezende","year":"2024","journal-title":"Arq Gastroenterol"},{"key":"R25-20260709","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R26-20260709","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2016.08.001","article-title":"Nonalcoholic fatty liver disease: updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-\u03b3 agonists.","volume":"66","author":"Polyzos","year":"2017","journal-title":"Metabolism"},{"key":"R27-20260709","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: an update.","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"R28-20260709","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canep.2014.02.002","article-title":"Colorectal cancer risk and dyslipidemia: a case-cohort study nested in an Italian multicentre cohort.","volume":"38","author":"Agnoli","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"R29-20260709","first-page":"257","article-title":"Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies.","volume":"26","author":"Yao","year":"2015","journal-title":"Cancer Causes Control"},{"key":"R30-20260709","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41366-023-01358-6","article-title":"Systemic adiponectin levels in colorectal cancer and adenoma: a systematic review and meta-analysis.","volume":"47","author":"Macleod","year":"2023","journal-title":"Int J Obes (Lond)"},{"key":"R31-20260709","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/joim.13343","article-title":"Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease.","volume":"292","author":"Hagstr\u00f6m","year":"2022","journal-title":"J Intern Med"},{"key":"R32-20260709","doi-asserted-by":"crossref","first-page":"101588","DOI":"10.1016\/j.clinre.2020.101588","article-title":"Statins use and the prognosis of colorectal cancer: a meta-analysis.","volume":"45","author":"Li","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R33-20260709","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.dsx.2015.09.005","article-title":"Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adults: Association of GGT and HOMA-IR with NAFLD.","volume":"10","author":"Hossain","year":"2016","journal-title":"Diabetes Metab Syndr"},{"key":"R34-20260709","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4291\/wjgp.v7.i2.211","article-title":"Insulin resistance in development and progression of nonalcoholic fatty liver disease.","volume":"7","author":"Alam","year":"2016","journal-title":"World J Gastrointest Pathophysiol"},{"key":"R35-20260709","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1186\/s12885-022-10100-w","article-title":"Association between the TyG index and TG\/HDL-C ratio as insulin resistance markers and the risk of colorectal cancer.","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Cancer"},{"key":"R36-20260709","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/liv.15763","article-title":"Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"44","author":"Souza","year":"2024","journal-title":"Liver Int"},{"key":"R37-20260709","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1158\/0008-5472.CAN-07-2924","article-title":"Circulating levels of inflammatory cytokines and risk of colorectal adenomas.","volume":"68","author":"Kim","year":"2008","journal-title":"Cancer Res"},{"key":"R38-20260709","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1440-1746.2009.06117.x","article-title":"Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps.","volume":"25","author":"Hwang","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"R39-20260709","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.3748\/wjg.v20.i28.9330","article-title":"Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.","volume":"20","author":"Mili\u0107","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R40-20260709","first-page":"9321643","article-title":"Gut microbiota as a driver of inflammation in nonalcoholic fatty liver disease.","volume":"2018","author":"Bibb\u00f2","year":"2018","journal-title":"Mediators Inflamm"},{"key":"R41-20260709","doi-asserted-by":"crossref","first-page":"346","DOI":"10.5217\/ir.2018.16.3.346","article-title":"Impact of microbiota in colorectal carcinogenesis: lessons from experimental models.","volume":"16","author":"Yu","year":"2018","journal-title":"Intest Res"},{"key":"R42-20260709","doi-asserted-by":"crossref","first-page":"e2205563","DOI":"10.1002\/advs.202205563","article-title":"Role of the gut microbiota and its metabolites in tumorigenesis or development of colorectal cancer.","volume":"10","author":"Qu","year":"2023","journal-title":"Adv Sci (Weinh)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:01:39Z","timestamp":1783616499000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":42,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049536","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"2026-03-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}